Elestat®
epinastine HCl 0.05% · ophthalmic solution
Allergy
Approved uses
Allergic conjunctivitis, prevention of itching
1 drop in each eye BID, continued throughout allergen exposure
Itch relief begins within 3 minutes and lasts at least 8 hours.
OFF-LABELNot in the FDA label for this product
Seasonal allergic conjunctivitis in soft contact lens wearers with shortened comfortable wear time
1 drop BID plus rewetting drops as needed, the regimen used in the trial
Open-label RCT · n=146
Randomized, open-label, multicenter trial during allergy season (N=146, 75 treated vs 71 on rewetting drops alone): mean comfortable wearing time rose 1.33 h vs 0.43 h (P=0.012) and total wearing time 0.35 h vs -0.32 h (P=0.008), with greater improvement in itch and overall comfort and fewer rewetting drop instillations. Read alongside the label, which states the product is not for contact lens-related irritation and that lenses come out before instillation.
Contraindications
None.
Ophthalmic solution, 5 mL fill in 10 mL bottle, 0.05% (0.5 mg/mL)
Topically active, direct H1-receptor antagonist and inhibitor of histamine release from the mast cell. Selective for the histamine H1-receptor, with affinity for the histamine H2-receptor and for the alpha-1, alpha-2, and 5-HT2 receptors.
Warnings & Precautions
- Use with contact lenses: Patients should not wear a contact lens if their eye is red, and epinastine HCl should not be used to treat contact lens-related irritation. The benzalkonium chloride preservative may be absorbed by soft contact lenses; remove lenses prior to instillation, and they may be reinserted after 10 minutes following administration.
- Contamination of tip and solution: Avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface, to avoid contamination by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. Keep the bottle tightly closed when not in use.
- Topical ophthalmic use only: For topical ophthalmic use only and not for injection or oral use.
Common Side Effects
The most frequently reported ocular adverse reactions, occurring in approximately 1% to 10% of patients, were burning sensation in the eye, folliculosis, hyperemia, and pruritus. The most frequently reported non-ocular adverse reactions were infection (cold symptoms and upper respiratory infections), seen in approximately 10% of patients, and headache, rhinitis, sinusitis, increased cough, and pharyngitis, seen in approximately 1% to 3% of patients. Increased lacrimation has been identified during postmarketing use.
Pregnancy: No adequate and well-controlled studies in pregnant women. Animal data show no drug-induced teratogenic effects, but total resorptions and abortion occurred in rabbits at an oral dose approximately 55,000 times the maximum recommended ocular human dose (MROHD), and reduced pup weight gain in rats at approximately 90,000 times the MROHD. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Excreted in the milk of lactating rats; excretion in human milk is unknown. Caution should be exercised when administered to a nursing woman.
Safety and effectiveness below age 2 not established.